Skip to content
RuleResource Intelligence

← All developments

CMS MLN Connects Weekly Newsletter · June 17, 2026 · Primary source

MLN Connects Newsletter for June 18, 2026

Score 76PRIMARYregulatoryCMS

Summary

The June 18, 2026 MLN Connects newsletter highlights two significant CMS actions. CMS issued a proposed rule (CMS-4215-P) to establish a permanent framework for the Medicare Drug Price Negotiation Program, covering negotiation and renegotiation of high-cost single-source drugs beginning with initial price applicability year 2029. CMS also issued a final rule, Strengthening Oversight of Accrediting Organizations and Preventing AO Conflicts of Interest, imposing enhanced oversight requirements on the more than 9,000 providers and suppliers accredited by CMS-approved AOs, including greater consistency between state survey agencies and AOs. An OIG compliance item notes that buprenorphine can decrease opioid use and overdose deaths, and that Medicare Part B covers OUD treatment services for as long as reasonable and necessary.

What this may mean

The final AO oversight rule creates new consistency requirements between AO survey processes and state survey agencies, affecting accredited hospitals, ASCs, and other providers subject to CMS-approved AO oversight. The proposed Medicare Drug Price Negotiation rule, if finalized, establishes a permanent framework affecting drug manufacturers whose products may be selected for negotiation beginning in 2029. The OIG buprenorphine finding reinforces coverage of OUD treatment under Medicare Part B and signals continued agency focus on medication-assisted treatment access.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.

Related items